|
Bacterial superinfection and antibiotic management in patients with COVID-19 admitted to intensive care medicine in central Iran: A follow-up study
Zary Nokhodian1, Soodabeh Rostami2, Parisa Zeraatei2, Marzieh Rahimkhorasani1, Saeed Abbasi3, Somayeh Sadeghi4
1 Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| Date of Submission | 08-Mar-2022 |
| Date of Acceptance | 08-Jun-2022 |
| Date of Web Publication | 25-Feb-2023 |
Correspondence Address:
Dr. Soodabeh Rostami
Infectious Diseases and Tropical Medicine Research Center, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/abr.abr_82_22
Background: Bacterial superinfections are one of the crucial challenges in patients with coronavirus disease 2019 (COVID-19) that are associated with a high mortality rate. The current study was designed to assess bacterial superinfections and antibiotic management in COVID-19 patients admitted to intensive care unit (ICU).
Material and Methods: Seventy-three adult intubated patients with COVID-19 were included in a cross-sectional study. The lung aspirate samples were collected in two stages and assessed for bacterial growth by standard methods. Antimicrobial susceptibility testing was performed using the Kirby-Bauer method as recommended by the Clinical Laboratory Standard Institute guideline (2021 edition). Also, demographic and clinical data were collected. The statistical analysis was done by chisquare test and Student's t-test, and a P value <0.05 was considered significant.
Results: Forty men and thirty-three women with a mean age of 64.78 ± 13.90 have included in our study. The mean length of hospitalization and stay in ICU were 18.77 ± 12.94 and 13.51 ± 9.83 days, respectively; 84.9% of cases died. Thirty-three patients had a bacterial superinfection mainly caused by Klebsiella spp and Acinetobacter spp; 21.2% of piperacillin/tazobactam consumers' patients survived that; the differences were significant (p = 0.034). A significant relationship was seen between superinfection and length of hospital stay until intubation (p = 0.033).
Conclusion: Bacterial superinfection and mortality rates were relatively high in COVID-19 patients admitted to ICU. According to the results, using beta-lactam/beta-lactamase inhibitors antibiotics in hospitalized patients in ICU can effectively control superinfection.
Keywords: Anti-bacterial agents, bacterial infections, COVID-19, intensive care units, superinfection
How to cite this article:
Nokhodian Z, Rostami S, Zeraatei P, Rahimkhorasani M, Abbasi S, Sadeghi S. Bacterial superinfection and antibiotic management in patients with COVID-19 admitted to intensive care medicine in central Iran: A follow-up study. Adv Biomed Res 2023;12:43 |
How to cite this URL:
Nokhodian Z, Rostami S, Zeraatei P, Rahimkhorasani M, Abbasi S, Sadeghi S. Bacterial superinfection and antibiotic management in patients with COVID-19 admitted to intensive care medicine in central Iran: A follow-up study. Adv Biomed Res [serial online] 2023 [cited 2023 Mar 23];12:43. Available from: https://www.advbiores.net/text.asp?2023/12/1/43/370389 |
| Introduction | |  |
Severe acute respiratory coronavirus 2 (SARS-CoV-2) first appeared in China in December 2019.[1] Since then, the virus has created a global pandemic that threatens the lives of billions of people on the earth. The advent of SARS-CoV-2 has presented severe challenges to health systems and physicians worldwide.[2],[3],[4] In this situation, Iran, like other countries in the world, with 6,175,782 cases of a definite diagnosis of the disease and 131,167 cases of death (till 22 December 2021), experiences a super-acute condition.[5]
SARS-CoV-2 is an RNA beta-coronavirus that, based on the phylogenetic tree, is related to SARS-CoV-1.[6],[7] The most prevalent symptoms are cough and fever.[4] However, the more serious outcomes, such as hospitalization in the intensive care unit (ICU) and the need for a ventilator are accompanied by a high mortality rate.[8],[9] It is estimated about 5 to 15% of patients with coronavirus disease 2019 (COVID-19) require hospitalization in the ICU and use of a ventilator due to severe respiratory problems.[1],[10] Studies in China and the United States show a high mortality rate in patients with COVID-19 admitted to the ICU.[2],[11],[12]
Insignificant outbreaks of respiratory infections and superinfections' role and importance are not clear. Patients with SARS-CoV-1, Middle East respiratory syndrome (MERS) coronavirus, and pandemic and seasonal influenza have various bacterial superinfections.[13] Bacterial superinfection has been repeatedly reported in influenza disease. While superinfection has been rarely seen in patients with SARS-CoV-1, and evidence show that superinfection does not occur in patients with MERS-CoV.[14],[15],[16],[17] The limited studies have assessed superinfection in patients who suffer from SARS-CoV-2, showing different results. The prevalence of bacterial superinfections varies among patients with COVID-19 admitted to the ICU from 28% to 100% in different countries.[18],[19],[20] A meta-analysis study reported that the prevalence is 14% in ICU.[13] Staphylococcus aureus, Haemophilus influenza, Streptococcus pneumonia, Enterobacteriaceae, Moraxella catarrhalis, and Acinetobacter baumannii were the most common bacteria identified in samples.[18],[19],[20]
Diagnosis of superinfections in patients with COVID-19, particularly in ICU, is challenging. The clinical symptoms, radiologic imaging, and inflammatory markers sometimes do not support each other and lead to misunderstanding and misdiagnosis. Information such as the prevalence of bacterial coinfections, essential risk factors, the frequent micro-organisms involved, and their antibiotic resistance can help physicians diagnose early and suitable treatment. This research aimed to identify respiratory tract bacterial superinfections in COVID patients admitted to the ICU in a referral hospital.
| Materials and Methods | | |
A cross-sectional study was conducted at AL-Zahra hospital in Isfahan, Iran, from April 11 until May 17, 2021. Al-Zahra hospital is a 700-bed university referral hospital that provides medical services for Isfahan province and the central region of Iran. All adult intubated patients over 18 years who suffered from COVID-19 and were admitted to three ICUs were included in the study. The COVID-19 was confirmed by a positive real-time- PCR (Polymerase chain reaction) test on a nasopharyngeal swab and/or clinical signs. The tracheal aspirate samples were collected in sterile tubes and immediately transferred to the laboratory. Sample collection was done in two stages: stage 1, when the patient was intubated in ICU or arrived intubated at the ICU, and stage 2, one week later if the patient was still intubated and alive. Superinfection was detected according to proper guidelines and clinical and para-clinical signs and symptoms.
The tracheal samples were cultures on the blood Agar, MacConkey Agar, and Chocolate Agar to identify the type of bacteria. Standard microbiology methods were used to confirm colonies grown on the plates. Antimicrobial susceptibility testing was performed using the Kirby-Bauer method for gram-positive and gram-negative bacteria, as recommended by the Clinical Laboratory Standard Institute (CLSI) guideline (2021 edition).
A checklist was completed for all cases from patients' electronic records, including demographic information (sex and age), laboratory test results including white blood cell count (WBC), C-reactive protein (CRP), Procalcitonin test (PCT), Erythrocyte sedimentation test (ESR), drugs including antibiotics and antivirals, corticosteroids, anticoagulants, mouthwashes, proton pump inhibitors, opioids and anesthetics, and length of stay in ICU and hospital.
Statistical analysis
Analyzes were performed using SPSS software (version 21, 2007, SPSS Inc., Chicago, IL, USA). Continuous and categorical variables were reported using mean with standard deviation (SD) and percentage, respectively. The Chi-square test and Student's t-test were used to analyze the data. P < 0.05 was statistically considered significant.
| Results | | |
From April 11 till May 17, 2021, 299 patients with COVID-19 were admitted to AL Zahra hospital ICUs, of whom 73 patients had inclusion criteria to enter the study. Twenty-two individuals had two samples. Forty men with a mean age of 66.20 ± 14.09 and thirty-three women with a mean age of 63.06 ± 13.69 years were included in our research. At the end of the study, 62 (84.9%) patients were died. The mean length of hospitalization was 18.77 ± 12.94 days, and the mean length of stay in ICU was 13.51 ± 9.83 days. There was a significant relationship between the duration from hospitalization to intubation in survived and dead patients (p = 0.033) [Table 1]. | Table 1: The main characteristic and biologic of patients with COVID-19 hospitalized in ICU
Click here to view |
Seventy-one participants received at least one antimicrobial drug during ICU stay, mostly with piperacillin/tazobactam (71.2%), meropenem (54.8%), and linezolid (42.5%). 21.2% of piperacillin/tazobactam consumers survived, that the differences were significant (p = 0.034). Corticosteroids (94.3%), Remdesivir (58.9%), anticoagulants (94.3%), mouthwash (68.6%), proton pump inhibitors (74.3%), opioids (98.6%), and anesthetics (100%) were used for patients.
Sex, age, length of hospitalization, length of hospital stays until intubation, and inflammatory markers did not show significant differences between patients with bacterial superinfection and without that [Table 2]. | Table 2: Demographic and clinical data of patients with and without bacterial superinfection
Click here to view |
Ninety-five respiratory tract secretion samples from 73 patients with COVID-19 cultured to detect of bacterial superinfection that 33 (45.2%) patients had positive culture. In total, 8 Klebsiella spp., 8 Acinetobacter spp., 6 S. aureus, 6 E. coli, 5 K. pneumoniae, 3 Acinetobacter calcoaceticus-baumannii complex, 1 S. epidermidis, 1 enterococcus spp., and 1 P. aeruginosa were detected [Table 3]. Of 15 patients who had two samples, in 6 patients, the bacterium isolated in the second sample was different from the bacteria isolated in the first sample. In seven cases, no bacteria were detected.
Of the 31 gram-negative isolates, 21/31; 68% were resistant to Ceftazidime, 24/31; 77.4% to cefepime, 21/31; 68% to imipenem and meropenem, 17/31; 54.8% to amikacin, and 20/31; 64.5% to levofloxacin. Also, 21/31; 68% of gram negative bacteria were multidrug-resistant (MDR).
Of the 8 gram positive bacteria 4 MRSA and one Vancomycin-resistant enterococci (VRE) were isolated [Table 3].
| Discussion | | |
COVID-19 is a new infection that weakens the patient's immune system and paves the way for more disorders. In the current study, bacterial superinfection was assessed among COVID-19 patients hospitalized in the ICU. Our results documented that 43.8% of patients with COVID-19 suffered from bacterial superinfection and the leading involved bacteria were Klebsiella spp and Acinetobacter spp. In a similar study in France, bacterial superinfection was reported in 28% of patients, and MRSA was the most frequent pathogen.[18] In the study by Lehmann et al.[21], bacterial superinfection among patients admitted to ICU was 41%. In a study in Iran, all patients were positive for bacterial superinfections; the most common organism was A. baumannii.[20] Fu et al.[22] reported that 13.9% of patients with COVID-19 admitted to ICU suffer from secondary bacterial infection. A meta-analysis showed that 14% of COVID-19 patients admitted to ICU suffer from bacterial superinfection.[13]
The most frequently involved bacteria in our study were Klebsiella spp. and Acinetobacter spp. In 2016, in a survey conducted in ICU within the same hospital, the common pathogens causing pneumonia were A. baumannii and K. pneumonia.[23] Sharifipour et al.[20] documented that the causative agent of infection in patients with COVID-19 in the ICU was A. baumannii and S. aureus. In another study in Iran, K. pneumonia and Acinetobacter were the most common organism in ICU.[24]
Factors such as the quality of care in ICU, the high workload of nurses in pandemic COVID-19, ICU type, and rate and type of used equipment can explain different results. However, the important things are that various studies document that bacterial superinfection can frequently occur in COVID-19 patients and be a severe threat to the patient's life.
It is possible that bacterial superinfection has developed in the ICU, and these were considered Intensive care unit acquired nosocomial infections. According to the results, the duration from hospitalization to intubation of patients was almost more than eight days. This data supports the occurrence of nosocomial infection for most of our patients. Another critical issue is that despite the frequency of bacterial superinfection in 43% of patients, antibiotic was used for 97.3% of subjects.
Unfortunately, in our study, 64.5% MDR gram-negative bacilli were isolated. Other studies do not support our results.[18],[20],[25] One of the reasons for the high prevalence of antibiotic resistance in these patients may be the using antibiotics for most of them (71/73; 97.3%) through ICU stay. During the COVID-19 pandemic, antibiotic stewardship programs (ASPs) became difficult to implement in the hospital. Therefore, one of the emergency measures of hospital managers should be the robust implementation of the ASP.
Our study has some limitations: I) Due to financial problems, we could not assess other superinfections in these patients. II) We did not have information about antibiotic therapy before ICU admission, which can prevent the growth of bacteria in the culture medium and potentially influence the real superinfection rate. III) Our research was done at a hospital, which influenced our results. Although, Al Zahra hospital is the biggest hospital in central Iran, we think the actual rate is near our results.
| Conclusion | | |
Bacterial superinfection and mortality rates were relatively high in COVID-19 patients admitted to ICU. According to the results, using beta-lactam/beta-lactamase inhibitors antibiotics in hospitalized patients in ICU can effectively control superinfection.
Ethical issues
The ethics Committee of Isfahan University of Medical Sciences, Isfahan, Iran, approved this study (approval number: IR.MUI.MEDREC.1399.065, Date of approve: 11/March/2021).
Acknowledgments
We appreciate the excellent support provided by ICU staff members.
Financial support and sponsorship
This study supported by Isfahan University of Medical Sciences, Isfahan, Iran, with grant Number 299173.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): A perspective from China. Radiology 2020;296:E15-25.  |
| 2. | Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054-62. |
| 3. | Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239-42. |
| 4. | Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med 2020;382:1708-20. |
| 5. | |
| 6. | Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020;395:565-74. |
| 7. | Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33. |
| 8. | Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Int Med 2020;180:934-43. |
| 9. | Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: A multicenter study of clinical features. Am J Respir Crit Care Med 2020;201:1380-8. |
| 10. | Möhlenkamp S, Thiele H. Ventilation of COVID-19 patients in intensive care units. Herz 2020;45:329-31. |
| 11. | Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020;201:1430-4. |
| 12. | Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020;323:1612-4. |
| 13. | Lansbury L, Lim B, Baskaran V, Lim WS. Superinfections in people with COVID-19: A systematic review and meta-analysis. J Infect 2020;81:266-75. |
| 14. | Joseph C, Togawa Y, Shindo N. Bacterial and viral infections associated with influenza. Influenza Other Respir Viruses 2013;7(Suppl 2):105-13. |
| 15. | Cox MJ, Loman N, Bogaert D, O'Grady J. Superinfections: Potentially lethal and unexplored in COVID-19. Lancet Microbe 2020;1:e11. |
| 16. | Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet Infect Dis 2013;13:752-61. |
| 17. | Zahariadis G, Gooley TA, Ryall P, Hutchinson C, Latchford MI, Fearon MA, et al. Risk of ruling out severe acute respiratory syndrome by ruling in another diagnosis: Variable incidence of atypical bacteria coinfection based on diagnostic assays. Can Respir J 2006;13:17-22. |
| 18. | Contou D, Claudinon A, Pajot O, Micaëlo M, Flandre PL, Dubert M, et al. Bacterial and viral superinfections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care 2020;10:1-9. |
| 19. | Verroken A, Scohy A, Gérard L, Wittebole X, Collienne C, Laterre P-F. Superinfections in COVID-19 critically ill and antibiotic management: A prospective cohort analysis. Crit Care 2020;24:1-3. |
| 20. | Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of bacterial superinfections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dis 2020;20:1-7. |
| 21. | Lehmann CJ, Pho MT, Pitrak D, Ridgway JP, Pettit NN. Community-acquired coinfection in coronavirus disease 2019: A retrospective observational experience. Clin Infect Dis 2021;72:1450-2. |
| 22. | Fu Y, Yang Q, Xu M, Kong H, Chen H, Fu Y, et al. Secondary bacterial infections in critical ill patients with coronavirus disease 2019. Open Forum Infect Dis 2020;7:ofaa220. |
| 23. | Alikiaii B, Aghadavoudi O, Emami N. Evauating antibiotic resistance pattern of ventilator-associated pnemonia in icu of Al Zahra hospital, ISFAHan university of medical sciences, Iran. J Isfahan Med Sch 2016;34:1083-9. |
| 24. | Sharifi A, Kavoosi F, Hosseini SMJ, Mosavat A, Ahmadi A. Prevalence of streptococcus pneumoniae in ventilator-associated pneumonia by real-time PCR. Arch Clin Infect Dis 2019;14:6. |
| 25. | Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of superinfections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study. Clin Microbiol Infect 2021;27:83-8. |
[Table 1], [Table 2], [Table 3]
|
Search Pubmed for